Agent that retards transformation of hormone-dependent cancer to non-hormone-dependent cancer

1 - 11 . (canceled)

12 . A method of retarding the transformation of a hormone-dependent cancer to a non-hormone dependent cancer in a mammal in need thereof, comprising administering to said mammal:

(i) a hormonal agent selected from 5-oxo-Pro-His-Trp-Ser-Tyr-DLeu-Leu-Arg-Pro-NH—C 2 H 5 (SEQ ID NO.: 2) or a salt thereof and cyproterone acetate, in combination with

(ii) a tyrosine kinase inhibitor of a cell growth factor receptor possessing tyrosine kinase activity;

wherein said tyrosine kinase inhibitor is administered after administration of said hormonal agent, (a) at a time the effective blood concentration of said hormonal agent has fallen below 50%, or (b) around the time a cell growth factor receptor begins to be expressed after administration of said hormonal agent.

13 . The method according to claim 12 , wherein said hormonal agent is 5-oxo-Pro-His-Trp-Ser-Tyr-DLeu-Leu-Arg-Pro-NH—C 2 H 5 (SEQ ID NO.: 2) or an acetate thereof.

14 . The method according to claim 12 , wherein said hormone-dependent cancer is prostatic cancer, ovarian cancer, cervical cancer or breast cancer.

15 . The method according to claim 12 , wherein said tyrosine kinase inhibitor is PD153035.

16 . A method of treating cancer in a mammal in need thereof by retarding the transformation of a hormone-dependent cancer to a non-hormone dependent cancer, comprising administering

(i) a hormonal agent selected from 5-oxo-Pro-His-Trp-Ser-Tyr-DLeu-Leu-Arg-Pro-NH—C 2 H 5 (SEQ ID NO.: 2) or a salt thereof, and cyproterone acetate in combination with

(ii) a tyrosine kinase inhibitor of a cell growth factor receptor possessing tyrosine kinase activity;

wherein said tyrosine kinase inhibitor is administered after administration of said hormonal agent, (a) at a time the effective blood concentration of said hormonal agent has fallen below 50%, or (b) around the time a cell growth factor receptor begins to be expressed after administration of said hormonal agent.

17 . A method of suppressing the metastasis or recurrence of a cancer by retarding the transformation of a hormone-dependent cancer to a non-hormone dependent cancer, in a mammal in need thereof, comprising administering

(i) a hormonal agent selected from 5-oxo-Pro-His-Trp-Ser-Tyr-DLeu-Leu-Arg-Pro NH—C 2 H 5 (SEQ ID NO.: 2) or a salt thereof, and cyproterone acetate in combination with

(ii) a tyrosine kinase inhibitor of a cell growth factor receptor possessing tyrosine kinase activity;

wherein said tyrosine kinase inhibitor is administered after administration of said hormonal agent, (a) at a time the effective blood concentration of said hormonal agent has fallen below 50%, or (b) around the time a cell growth factor receptor begins to be expressed after administration of said hormonal agent.

18 - 20 . (canceled)

21 . The method according to claim 16 , wherein said hormonal agent is 5-oxo-Pro-His-Trp-Ser-Tyr-DLeu-Leu-Arg-Pro-NH—C 2 H 5 (SEQ ID NO.: 2) or an acetate thereof.

22 . The method according to claim 16 , wherein said hormone-dependent cancer is prostatic cancer, ovarian cancer, or breast cancer.

23 . The method according to claim 16 , wherein said tyrosine kinase inhibitor is PD153035.

24 . The method according to claim 17 , wherein said hormonal agent is 5-oxo-Pro-His-Trp-Ser-Tyr-DLeu-Leu-Arg-Pro-NH—C 2 H 5 (SEQ ID NO.: 2) or an acetate thereof.

25 . The method according to claim 17 , wherein said hormone-dependent cancer is prostatic cancer, ovarian cancer, or breast cancer.

26 . The method according to claim 17 , wherein said tyrosine kinase inhibitor is PD153035.

27 . The method according to claim 12 , wherein said hormone-dependent cancer is prostatic cancer.

28 . The method according to claim 16 , wherein said hormone-dependent cancer is prostatic cancer.

29 . The method according to claim 17 , wherein said hormone-dependent cancer is prostatic cancer.